NEXAGON
Phase 1- Indications
- Persistent corneal epithelial defect
Company intelligence / Profile preview
OcuNexus Therapeutics
San Diego, California, United Statesprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
OcuNexus Therapeutics is a clinical-stage biopharmaceutical company developing therapies that modulate the inflammasome pathway by targeting the Connexin43 hemichannel. Its lead asset, lufepirsen (Nexagon), an antisense oligonucleotide, is in Phase II/III trials for corneal injuries and has orphan drug designation. The company also develops small molecule modulators for ophthalmic and renal indications such as dry AMD, diabetic retinopathy, and diabetic nephropathy. Clinical data suggest efficacy in reducing inflammation and tissue damage across multiple tissue types.[2][3][4][5]
- Therapeutic areas
- OphthalmologyNephrology
- Modalities
- Small moleculesAntisense oligonucleotides (e.g., lufepirsen/Nexagon)[5]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Eyevance Pharmaceuticals listed as a developer of lufepirsen alongside OcuNexus.[5]
Beyond the preview
Go deeper on OcuNexus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OcuNexus Therapeutics.